Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.25−0.35 (-0.34%)
Close on Nov 12, 2026Market cap $6.61BP/E 25.0Yield –
Lantheus ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lantheus's ebitda for the twelve months ending Sep 30, 2026 was $381.93M, down 7.3% year over year. For fiscal 2025 it was $380.93M, down 27.0% from the year before. Over ten years it grew 19.9% a year on average. The highest annual figure on record is $521.60M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $380.93M | -27.0% |
| FY2024 | Dec 31, 2024 | $521.60M | +22.8% |
| FY2023 | Dec 31, 2023 | $424.69M | +404.8% |
| FY2022 | Dec 31, 2022 | $84.12M | – |
| FY2021 | Dec 31, 2021 | -$18.54M | -190.5% |
| FY2020 | Dec 31, 2020 | $20.49M | -68.5% |
| FY2019 | Dec 31, 2019 | $65.04M | -17.1% |
| FY2018 | Dec 31, 2018 | $78.42M | +10.3% |
| FY2017 | Dec 31, 2017 | $71.08M | -5.0% |
| FY2016 | Dec 31, 2016 | $74.85M | +20.4% |
| FY2015 | Dec 31, 2015 | $62.18M | +6.4% |
| FY2014 | Dec 31, 2014 | $58.44M | +748.0% |
| FY2013 | Dec 31, 2013 | $6.89M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $55.10M | -13.9% |
| Q2 FY2026 | Jun 30, 2026 | $122.80M | +21.3% |
| Q1 FY2026 | Mar 31, 2026 | $104.01M | -10.1% |
| Q4 FY2025 | Dec 31, 2025 | $100.02M | -23.7% |
| Q3 FY2025 | Sep 30, 2025 | $64.02M | -57.5% |
| Q2 FY2025 | Jun 30, 2025 | $101.20M | -13.9% |
| Q1 FY2025 | Mar 31, 2025 | $115.69M | -5.2% |
| Q4 FY2024 | Dec 31, 2024 | $131.16M | -14.0% |
| Q3 FY2024 | Sep 30, 2024 | $150.82M | +30.8% |
| Q2 FY2024 | Jun 30, 2024 | $117.55M | -7.8% |
| Q1 FY2024 | Mar 31, 2024 | $122.08M | +2216.1% |
| Q4 FY2023 | Dec 31, 2023 | $152.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $115.26M | +28.6% |
| Q2 FY2023 | Jun 30, 2023 | $127.44M | +91.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.27M | -92.5% |
| Q4 FY2022 | Dec 31, 2022 | -$159.80M | – |
| Q3 FY2022 | Sep 30, 2022 | $89.64M | – |
| Q2 FY2022 | Jun 30, 2022 | $66.50M | – |
| Q1 FY2022 | Mar 31, 2022 | $70.71M | +197.8% |
| Q4 FY2021 | Dec 31, 2021 | -$23.14M | -394.2% |
| Q3 FY2021 | Sep 30, 2021 | -$10.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.58M | – |
| Q1 FY2021 | Mar 31, 2021 | $23.75M | +118.7% |
| Q4 FY2020 | Dec 31, 2020 | $7.87M | -50.8% |
| Q3 FY2020 | Sep 30, 2020 | -$1.85M | -116.8% |
| Q2 FY2020 | Jun 30, 2020 | -$2.85M | -116.7% |
| Q1 FY2020 | Mar 31, 2020 | $10.86M | -44.3% |
| Q4 FY2019 | Dec 31, 2019 | $15.98M | -21.4% |
| Q3 FY2019 | Sep 30, 2019 | $11.02M | -42.0% |
| Q2 FY2019 | Jun 30, 2019 | $17.04M | -7.5% |
| Q1 FY2019 | Mar 31, 2019 | $19.49M | +4.1% |
| Q4 FY2018 | Dec 31, 2018 | $20.33M | +51.5% |
| Q3 FY2018 | Sep 30, 2018 | $18.98M | +14.6% |
| Q2 FY2018 | Jun 30, 2018 | $18.43M | -19.9% |
| Q1 FY2018 | Mar 31, 2018 | $18.73M | +3.6% |
| Q4 FY2017 | Dec 31, 2017 | $13.42M | -24.4% |
| Q3 FY2017 | Sep 30, 2017 | $16.57M | – |
| Q2 FY2017 | Jun 30, 2017 | $23.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $18.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.74M | – |
See a number that looks wrong?